Baxter International Faces Class Action Over Novum LVP Device Defects and Securities Fraud
- Baxter International faces class action lawsuits alleging securities fraud regarding defects in its Novum Large Volume Pump devices.
- The lawsuits claim Baxter failed to disclose serious malfunctions, risking patient safety and misleading investors about product integrity.
- Investors affected by stock losses from February 2022 to July 2025 can participate in the class action until December 2025.
Baxter International Faces Allegations Over Novum LVP Device Defects
In a significant legal development for Baxter International, Inc. (NYSE: BAX), multiple law firms announce class action lawsuits against the company, alleging securities fraud related to its Novum Large Volume Pump (LVP) devices. The lawsuits claim that Baxter failed to disclose critical issues with the Novum LVPs, which reportedly suffered from systemic defects that led to severe malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids. These defects pose serious risks to patient safety, raising concerns about the company's operational integrity and the safety of its products.
The complaints assert that Baxter was aware of numerous malfunctions and associated injuries but did not adequately address these issues, failing to provide sufficient customer alerts regarding the risks. The lawsuits highlight that Baxter's purportedly positive statements about its business operations and the safety of its products were materially misleading. As a result of these alleged omissions and misrepresentations, there is a growing fear among investors that customers might withdraw the Novum LVPs from use, leading to a potential halt in new sales and a significant impact on the company's market position.
Investors who experienced losses related to Baxter’s stock during the specified period from February 23, 2022, to July 30, 2025, are encouraged to participate in the class action. They have until December 15, 2025, to act as lead plaintiffs if they choose. The announcements from various law firms indicate a collective effort to hold Baxter accountable and to provide a pathway for affected investors to seek justice and potential recovery for their losses.
In addition to the ongoing legal proceedings, Baxter International faces mounting scrutiny over the safety and efficacy of its medical devices. The Novum LVP's alleged defects could lead to increased regulatory scrutiny and a potential loss of consumer trust, which may have long-term ramifications for the company’s reputation and financial performance. As patient safety remains a paramount concern in the healthcare industry, Baxter's response to these allegations will be closely monitored by stakeholders.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

